American Association for Cancer Research
Browse
crc-22-0027-s01.pdf (2.67 MB)

Supplementary Figures S1-S8 from The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models

Download (2.67 MB)
journal contribution
posted on 2023-04-04, 01:24 authored by Shoshy A. Brinch, Enya Amundsen-Isaksen, Sandra Espada, Clara Hammarström, Aleksandra Aizenshtadt, Petter A. Olsen, Lone Holmen, Merete Høyem, Hanne Scholz, Gunnveig Grødeland, Sven T. Sowa, Albert Galera-Prat, Lari Lehtiö, Ilonka A.T.M. Meerts, Ruben G.G. Leenders, Anita Wegert, Stefan Krauss, Jo Waaler

Supplementary Figure S1. Chemical structures of selected tankyrase inhibitors. Supplementary Figure S2. OM-153 specifically inhibits TNKS1/2 and WNT/β-catenin signaling. Supplementary Figure S3. OM-153 specifically inhibits cell growth of an APC-mutated colon carcinoma cell line. Supplementary Figure S4. OM-153 shows an anti-proliferative effect in human cancer cell lines. Supplementary Figure S5. OM-153 inhibits WNT/β-catenin, YAP and MYC signaling in human cancer cell lines. Supplementary Figure S6. OM-153 inhibits the WNT/β-catenin signaling pathway and shows anti-tumor effect in a human colon carcinoma xenograft model. Supplementary Figure S7. Combined OM-153 and anti-PD-1 treatment confers anti-tumor effect in mouse melanoma. Supplementary Figure S8. PO-BID treatment with 10 mg/kg OM-153 does not reduce body weight and food consumption or induce toxicity in mice.

Funding

South-Eastern Norway Regional Health Authority

Research Council of Norway

Jane and Aatos Erkko Foundation

History

ARTICLE ABSTRACT

This study uncovers the effectiveness and therapeutic window for a novel tankyrase inhibitor in mouse tumor models.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC